Literature DB >> 33589762

Blood pressure categories defined by the 2017 ACC/AHA guideline and all-cause mortality: a national cohort study in China and meta-analysis.

Jiaxiang Wang1, Jieyu Liu1, Haoyue Teng1, Yushan Zhang1, Xingxuan Dong1, Wei Chen2, Jieyun Yin3.   

Abstract

The 2017 American College of Cardiology/American Heart Association guideline recommends a lowered threshold for hypertension diagnosis. Nonetheless, the association of blood pressure (BP) groups defined by the new guideline and all-cause mortality has not been fully estimated, especially in general Chinese. Based on the China Health and Retirement Longitudinal Study (CHARLS) during 2011-2018, 12,964 participants aged 45 years or older at baseline were enrolled for a follow-up of 7 years. Cox proportional hazards models were used to examine the relationship of BP classifications with all-cause mortality, with normal BP (<120/80 mmHg) as a reference. Afterwards, eligible studies shed light in this field were searched in public databases, and meta-analysis was conducted. In CHARLS, there were 41.21% and 16.08% individuals with stage 2 hypertension and stage 1 hypertension, respectively. During the follow-up, 1293 death occurred. The redefined stage 1 (130-139/80-89 mmHg) and stage 2 hypertension (≥140/≥90 mmHg) were found to have increased risk of death in the crude model, but only stage 2 hypertension maintained statistically significance after adjustment. Furthermore, meta-analysis including CHARLS and nine other prospective studies, with a total of 290,609 participants followed up for 3,081,532 person-years, resulted in similar results (combined hazard ratio (95% confidence interval) was 1.07 (0.99-1.15) for stage 1 hypertension, and 1.39 (1.25-1.53) for stage 2 hypertension). The present study detected that individuals with stage 2 and stage 1 hypertension had increased likelihood to die from any cause, but only the former association achieved statistically significance. Further cohorts with long-term follow-up duration are warranted, especially in China.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.

Entities:  

Mesh:

Year:  2021        PMID: 33589762     DOI: 10.1038/s41371-021-00495-7

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  34 in total

Review 1.  Selected major risk factors and global and regional burden of disease.

Authors:  Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn; Christopher J L Murray
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

Review 2.  Psychosomatic sequelae of hypertension labelling.

Authors:  Willem H Birkenhäger
Journal:  J Hypertens       Date:  2003-07       Impact factor: 4.844

3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

4.  2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-10       Impact factor: 4.844

5.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

6.  Association between depression and hypertension using classic and revised blood pressure thresholds.

Authors:  Dustin S DeMoss; Kari J Teigen; Cynthia A Claassen; Mandy J Fisk; Somer E Blair; Sulaimon A Bakre; Cheryl L Hurd; Augustus J Rush
Journal:  Fam Pract       Date:  2020-10-19       Impact factor: 2.267

7.  Burden of hypertension in China: A nationally representative survey of 174,621 adults.

Authors:  Yichong Li; Ling Yang; Limin Wang; Mei Zhang; Zhengjing Huang; Qian Deng; Maigeng Zhou; Zhengming Chen; Linhong Wang
Journal:  Int J Cardiol       Date:  2016-11-02       Impact factor: 4.164

8.  Hypertension labelling was associated with poorer self-rated health in the Third US National Health and Nutrition Examination Survey.

Authors:  S D Barger; M F Muldoon
Journal:  J Hum Hypertens       Date:  2006-02       Impact factor: 3.012

9.  Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project).

Authors:  Jiapeng Lu; Yuan Lu; Xiaochen Wang; Xinyue Li; George C Linderman; Chaoqun Wu; Xiuyuan Cheng; Lin Mu; Haibo Zhang; Jiamin Liu; Meng Su; Hongyu Zhao; Erica S Spatz; John A Spertus; Frederick A Masoudi; Harlan M Krumholz; Lixin Jiang
Journal:  Lancet       Date:  2017-11-05       Impact factor: 79.321

10.  Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study.

Authors:  Rohan Khera; Yuan Lu; Jiapeng Lu; Anshul Saxena; Khurram Nasir; Lixin Jiang; Harlan M Krumholz
Journal:  BMJ       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.